Amivantamab-Lazertinib Combination Therapy in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Critical Analysis of Recent Clinical Evidence

A multicenter randomized controlled trial demonstrates notable efficacy outcomes for dual-targeted therapy in EGFR-mutated advanced NSCLC, though several methodological considerations warrant examination.